

Know How Bexagliflozin Stacks Up to Other SGLT2 Inhibitors

New bexagliflozin (*Brenzavvy*) will try to shake up the SGLT2 inhibitor market.

That's because bexagliflozin will cost about \$50/mo...versus about \$600/mo for other SGLT2 inhibitors (dapagliflozin, etc).

But bexagliflozin won't be covered by most payers yet...and it will only be available through a single online pharmacy at first. Expect distribution to broaden over the next couple months.

Know how bexagliflozin stacks up to the competition.

Bexagliflozin is ONLY approved for managing type 2 diabetes. It lowers A1c about 0.5%...similar to other SGLT2 inhibitors.

So far, evidence isn't strong enough to say that bexagliflozin improves cardiorenal outcomes like some SGLT2 inhibitors.

But cardiorenal benefits are likely a class effect.

For example, data show that all 5 other SGLT2 inhibitors reduce risk of heart failure hospitalization.

And there's good evidence that canagliflozin, dapagliflozin, or empagliflozin reduce chronic kidney disease progression.

Continue to recommend an SGLT2 inhibitor based on indication and payer preference.

For instance, try to use an SGLT2 inhibitor with proven benefit if one of these meds is needed to reduce risk of CV events, heart failure, or chronic kidney disease progression.

But don't shy away from bexagliflozin for one of these uses if other SGLT2 inhibitors aren't accessible for your patient.

Or consider bexagliflozin if a patient only needs an SGLT2 inhibitor for type 2 diabetes.

If thinking about bexagliflozin, ensure that its \$50/month cost is less than the out-of-pocket expense for other SGLT2 inhibitors.

Caution about key risks with any SGLT2 inhibitor...genital yeast infections, volume depletion, rare Fournier's gangrene, etc.

For a deeper dive into the evidence for SGLT2 inhibitors, see our resource, *Diabetes Medications: Cardiovascular and Kidney Impact*.

Key References:

- Bexagliflozin Efficacy and Safety Trial (BEST) July 14, 2021.
<https://clinicaltrials.gov/study/NCT02558296?term=bexagliflozin&rank=3&tab=results> (Accessed August 18, 2023).
- Halvorsen YD, Conery AL, Lock JP, et al. Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial. *Diabetes Obes Metab.* 2023 Jul 6. doi: 10.1111/dom.15192.
- Allegretti AS, Zhang W, Zhou W, et al. Safety and Effectiveness of Bexagliflozin in Patients With Type 2

Cite this document as follows: Article, Know How Bexagliflozin Stacks Up to Other SGLT2 Inhibitors, Prescriber's Letter, September 2023

The content of this article is provided for educational and informational purposes only, and is not a substitute for the advice, opinion or diagnosis of a trained medical professional. If your organization is interested in an enterprise subscription, email sales@trchealthcare.com.

© 2023 Therapeutic Research Center (TRC). TRC and Prescriber's Letter and the associated logo(s) are trademarks of Therapeutic Research Center. All Rights Reserved.

Diabetes Mellitus and Stage 3a/3b CKD. Am J Kidney Dis. 2019 Sep;74(3):328-337.
-Medication pricing by Elsevier, accessed Aug 2023.

Pharmacist's Letter. September 2023, No. 390904

Cite this document as follows: Article, Know How Bexagliflozin Stacks Up to Other SGLT2 Inhibitors, Prescriber's Letter, September 2023

The content of this article is provided for educational and informational purposes only, and is not a substitute for the advice, opinion or diagnosis of a trained medical professional. If your organization is interested in an enterprise subscription, email sales@trchealthcare.com.

© 2023 Therapeutic Research Center (TRC). TRC and Prescriber's Letter and the associated logo(s) are trademarks of Therapeutic Research Center. All Rights Reserved.